The cooperative induction of hypoxia-inducible factor-1α and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis

Journal of Immunology

Volumn 182, Issue 6, 2009, Pages 3510-3521

  Noman, Muhammad Zaeem ^a   Buart, Stéphanie ^a   Van Pelt, Jos ^b   Richon, Catherine ^a   Hasmim, Meriem ^a   Leleu, Nathalie ^a   Suchorska, Wictoria Maria ^a   Jalil, Abdelali ^a   Lecluse, Yann ^a   El Hage, Faten ^a   Giuliani, Massimo ^c   Pichon, Christophe ^a   Azzarone, Bruno ^c   Mazure, Nathalie ^d   Romero, Pedro ^e   Mami Chouaib, Fathia ^a   Chouaib, Salem ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSERM   (France)

^d CNRS   (France)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GRANZYME B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; STAT3 PROTEIN; VASCULOTROPIN; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER SUSCEPTIBILITY; CELL STRUCTURE; CONTROLLED STUDY; CYTOLYSIS; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG NON SMALL CELL CANCER; MICROENVIRONMENT; OXYGEN TENSION; POLARIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TARGET CELL; TUMOR CELL; TUMOR CELL CULTURE; WESTERN BLOTTING; ANOXIA; BIOSYNTHESIS; CELL CLONE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANOXIA; CELL LINE, TUMOR; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNITY, INNATE; LUNG NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 65449154326     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0800854     Document Type: Article

References (54)

1. Rosenberg, S. A. 2001. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250: 462-475.
2. Lieberman, J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3: 361-370.
3. Trapani, J. A., and M. J. Smyth. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2: 735-747.
4. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18: 493-497.
5. Chouaib, S. 2003. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J. Clin. Invest. 111: 595-597.
6. + T lymphocytes. J. Immunol. 177: 4962-4965.
7. Aebersold, D. M., P. Burri, K. T. Beer, J. Laissue, V. Djonov, R. H. Greiner, and G. L. Semenza. 2001. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61: 2911-2916.
8. 2 tension. Proc. Natl. Acad. Sci. USA 92: 5510-5514.
9. Wenger, R. H., D. P. Stiehl, and G. Camenisch. 2005. Integration of oxygen signaling at the consensus HRE. Sci. STKE 2005: re12.
10. Semenza, G. L. 2000. Chairman's summary: mechanisms of oxygen homeostasis, circa 1999. Adv. Exp. Med. Biol. 475: 303-310.
11. Harris, A. L. 2002. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev Cancer 2: 38-47.
12. Moeller, B. J., and M. W. Dewhirst. 2004. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3: 1107-1110.
13. Unruh, A., A. Ressel, H. G. Mohamed, R. S. Johnson, R. Nadrowitz, E. Richter, D. M. Katschinski, and R. H. Wenger. 2003. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 22: 3213-3220.
14. Giaccia, A., B. G. Siim, and R. S. Johnson. 2003. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2: 803-811.
15. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3: 721-732.
16. Xu, Q., J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G. L. Semenza, et al. 2005. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560.
17. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell, Jr. 1999. Stat3 as an oncogene. Cell 98: 295-303.
18. Catlett-Falcone, R., W. S. Dalton, and R. Jove. 1999. STAT proteins as novel targets for cancer therapy: signal transducer an activator of transcription. Curr. Opin. Oncol. 11: 490-496.
19. Bowman, T., M. A. Broome, D. Sinibaldi, W. Wharton, W. J. Pledger, J. M. Sedivy, R. Irby, T. Yeatman, S. A. Courtneidge, and R. Jove. 2001. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98: 7319-7324.
20. Germain, D., and D. A. Frank. 2007. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 13: 5665-5669.
21. Al Zaid Siddiquee, K., and J. Turkson. 2008. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18: 254-267.
22. Dayan, F., D. Roux, M. C. Brahimi-Horn, J. Pouyssegur, and N. M. Mazure. 2006. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1α. Cancer Res. 66: 3688-3698.
23. Echchakir, H., F. Mami-Chouaib, I. Vergnon, J. F. Baurain, V. Karanikas, S. Chouaib, and P. G. Coulie. 2001. A point mutation in the α-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 61: 4078-4083.
24. Dorothee, G., I. Vergnon, F. El Hage, B. Le Maux Chansac, V. Ferrand, Y. Lecluse, P. Opolon, S. Chouaib, G. Bismuth, and F. Mami-Chouaib. 2005. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J. Immunol. 174: 6888-6897.
25. Echchakir, H., I. Vergnon, G. Dorothee, D. Grunenwald, S. Chouaib, and F. Mami-Chouaib. 2000. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int. Immunol. 12: 537-546.
26. Lund, E. L., L. T. Hansen, and P. E. Kristjansen. 2005. Augmenting tumor sensitivity to topotecan by transient hypoxia. Cancer Chemother. Pharmacol. 56: 473-480.
27. Asselin-Paturel, C., S. Megherat, I. Vergnon, H. Echchakir, G. Dorothee, S. Blesson, F. Gay, F. Mami-Chouaib, and S. Chouaib. 2001. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction. Cancer 91: 113-122.
28. Dorothee, G., H. Echchakir, B. Le Maux Chansac, I. Vergnon, F. El Hage, A. Moretta, A. Bensussan, S. Chouaib, and F. Mami-Chouaib. 2003. Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma. Oncogene 22: 7192-7198.
29. Dasgupta, P., R. Kinkade, B. Joshi, C. Decook, E. Haura, and S. Chellappan. 2006. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc. Natl. Acad. Sci. USA 103: 6332-6337.
30. Abouzahr, S., G. Bismuth, C. Gaudin, O. Caroll, P. Van Endert, A. Jalil, J. Dausset, I. Vergnon, C. Richon, A. Kauffmann, et al. 2006. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc. Natl. Acad. Sci. USA 103: 1428-1433.
31. Diarra-Mehrpour, M., S. Arrabal, A. Jalil, X. Pinson, C. Gaudin, G. Pietu, A. Pitaval, H. Ripoche, M. Eloit, D. Dormont, and S. Chouaib. 2004. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor α-induced cell death. Cancer Res. 64: 719-727.
32. Wittnebel, S., A. Jalil, J. Thiery, S. DaRocha, E. Viey, B. Escudier, S. Chouaib, and A. Caignard. 2005. The sensitivity of renal cell carcinoma cells to interferon α correlates with p53-induction and involves Bax. Eur. Cytokine Netw. 16: 123-127.
33. Hamai, A., C. Richon, F. Meslin, F. Faure, A. Kauffmann, Y. Lecluse, A. Jalil, L. Larue, M. F. Avril, S. Chouaib, and M. Mehrpour. 2006. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene 25: 7618-7634.
34. Dorothee, G., M. Ameyar, A. Bettaieb, I. Vergnon, H. Echchakir, M. Bouziane, S. Chouaib, and F. Mami-Chouaib. 2001. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells. Int. J. Cancer 91: 772-777.
35. Thiery, J., G. Dorothee, H. Haddada, H. Echchakir, C. Richon, R. Stancou, I. Vergnon, J. Benard, F. Mami-Chouaib, and S. Chouaib. 2003. Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J. Immunol. 170: 5919-5926.
36. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51.
37. Lieblein, J. C., S. Ball, B. Hutzen, A. K. Sasser, H. J. Lin, T. H. Huang, B. M. Hall, and J. Lin. 2008. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 8: 302.
38. Blaskovich, M. A., J. Sun, A. Cantor, J. Turkson, R. Jove, and S. M. Sebti. 2003. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63: 1270-1279.
39. Van den Eynde, B. J., and P. van der Bruggen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9: 684-693.
40. Yoshino, I., P. S. Goedegebuure, G. E. Peoples, A. S. Parikh, J. M. DiMaio, H. K. Lyerly, A. F. Gazdar, and T. J. Eberlein. 1994. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54: 3387-3390.
41. Marchand, M., C. J. Punt, S. Aamdal, B. Escudier, W. H. Kruit, U. Keilholz, L. Hakansson, N. van Baren, Y. Humblet, P. Mulders, et al. 2003. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39: 70-77.
42. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.
43. Albini, A., and M. B. Sporn. 2007. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7: 139-147.
44. MacDonald, H. R., and C. J. Koch. 1977. Energy metabolism and T cell-mediated cytolysis. I. Synergism between inhibitors of respiration and glycolysis. J. Exp. Med. 146: 698-709.
45. Lee, A., J. S. Morrow, and V. M. Fowler. 2001. Caspase remodeling of the spectrin membrane skeleton during lens development and aging. J. Biol. Chem. 276: 20735-20742.
46. Volm, M., and R. Koomagi. 2000. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 20: 1527-1533.
47. Erler, J. T., C. J. Cawthorne, K. J. Williams, M. Koritzinsky, B. G. Wouters, C. Wilson, C. Miller, C. Demonacos, I. J. Stratford, and C. Dive. 2004. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol. 24: 2875-2889.
48. Liu, X. H., E. Z. Yu, Y. Y. Li, and E. Kagan. 2006. HIF-1α has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J. Cell. Biochem. 97: 755-765.
49. Semenza, G. L. 2002. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64: 993-998.
50. Jung, J. E., H. G. Lee, I. H. Cho, D. H. Chung, S. H. Yoon, Y. M. Yang, J. W. Lee, S. Choi, J. W. Park, S. K. Ye, and M. H. Chung. 2005. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 19: 1296-1298.
51. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10: 48-54.
52. Hussain, S. F., L. Y. Kong, J. Jordan, C. Conrad, T. Madden, I. Fokt, W. Priebe, and A. B. Heimberger. 2007. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 67: 9630-9636.
53. Gabrilovich, D. I., T. Ishida, S. Nadaf, J. E. Ohm, and D. P. Carbone. 1999. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 5: 2963-2970.
54. Nair, S., D. Boczkowski, B. Moeller, M. Dewhirst, J. Vieweg, and E. Gilboa. 2003. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102: 964-971.